Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | FLT1 | P17948 | 15/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 10/20 | 1.00 |
| ▸ | FLT4 | P35916 | 6/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 7/20 | 0.84 |
| ▸ | SRC | P12931 | 1/20 | 0.78 |
| ▸ | RET | P07949 | 2/20 | 0.76 |
| ▸ | KIF5B | P33176 | 2/20 | 0.76 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.71 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.71 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012896 | 1.00 | KDR (1.00) | KDRFLT1FGFR1FLT4EPHB2 | |
| Hydrochloric Acid SCHEMBL7867640 | 0.99 | KDR (0.98) | KDRFLT1FGFR1FLT4EPHB2 | |
| Hydrochloric Acid SCHEMBL30078372 | 0.99 | KDR (0.98) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL1468310 | 0.92 | FLT1 (0.85) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL7867151 | 0.92 | FLT1 (1.00) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL21557447 | 0.91 | KDR (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL1467058 | 0.91 | KDR (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL7864752 | 0.91 | FLT1 (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| SCHEMBL7867708 | 0.91 | FLT1 (0.83) | KDRFLT1FGFR1FLT4EPHB2 | |
| Hydrochloric Acid SCHEMBL7859481 | 0.91 | FLT1 (0.98) | KDRFLT1FGFR1FLT4EPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346635-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 (VEGFR-1) INHIBITORS FOR PROMOTING MYELINATION AND NEUROPROTECTION | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÉRE) (FR) | 2025-11-13 | — | — | US | claimed |
| EP-4547252-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 (VEGFR-1) INHIBITORS FOR PROMOTING MYELINATION AND NEUROPROTECTION | ICM (Institut du Cerveau et de la Moelle Épinière) (FR) | 2025-05-07 | — | — | EP | claimed |
| EP-4539924-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND VEGF INHIBITORS | Novocure GmbH (CH) | 2025-04-23 | — | — | EP | claimed |
| CN-119451723-A | Compositions, systems, and methods for treating cancer using a tumor treating electric field and a VEGF inhibitor | 诺沃库勒有限责任公司 | 2025-02-14 | — | — | CN | claimed |
| US-20240336977-A1 | MICRORNA-REGULATED BIOMARKERS AND DRUG TARGETS FOR IMPROVING DIAGNOSIS AND TREATMENT OF LUNG OR BREAST CANCER | West Virginia University Board of Governors on behalf of West Virginia University (US) | 2024-10-10 | — | — | US | claimed |
| US-20240200147-A1 | Non-Small Cell Lung Cancer Diagnosis and Treatment | THE WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY | 2024-06-20 | — | — | US | claimed |
| WO-2024003380-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 (VEGFR-1) INHIBITORS FOR PROMOTING MYELINATION AND NEUROPROTECTION | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2024-01-04 | — | — | WO | claimed |
| WO-2023248139-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND VEGF INHIBITORS | NOVOCURE GMBH (CH) | 2023-12-28 | — | — | WO | claimed |
| US-20230405316-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND VEGF INHIBITORS | NOVOCURE GMBH (CH) | 2023-12-21 | — | — | US | claimed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | claimed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250346635-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 (VEGFR-1) INHIBITORS FOR PROMOTING MYELINATION AND NEUROPROTECTION | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÉRE) (FR) | 2025-11-13 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250283077-A1 | ENHANCED HAMMERHEAD RIBOZYMES AND METHODS OF USE | US GOV VETERANS AFFAIRS (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | KARUS THERAPEUTICS LIMITED (GB) | 2022-04-05 | — | — | US | disclosed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11234955-B2 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-02-01 | — | — | US | disclosed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346635-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 (VEGFR-1) INHIBITORS FOR PROMOTING MYELINATION AND NEUROPROTECTION | FLT1, KDR, FLT4 | KDR 2/4885FLT1 1/4885FGFR1 50/4885 |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | KDR 1380/4885FLT1 1971/4885FGFR1 2333/4885 |
| US-11234955-B2 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma | MGMT, MPG, HDAC7 | KDR 2810/4885FLT1 2692/4885FGFR1 2862/4885 |
| US-20240200147-A1 | Non-Small Cell Lung Cancer Diagnosis and Treatment | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PDCD1, PDCD10 | KDR 4597/4885FLT1 2543/4885FGFR1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.